AARD saw its Momentum Indicator move below the 0 level on October 01, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator turned negative. In 21 of the 23 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for AARD turned negative on October 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 17 similar instances when the indicator turned negative. In 14 of the 17 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AARD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for AARD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AARD's RSI Indicator exited the oversold zone, 6 of 9 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 15 of 16 cases where AARD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
Following a +17.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where AARD advanced for three days, in 87 of 100 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
AARD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.156) is normal, around the industry mean (2.973). P/E Ratio (-1.227) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. AARD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AARD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ACAD advanced for three days, in 189 of 253 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ACAD's RSI Indicator exited the oversold zone, 15 of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on ACAD as a result. In 71 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for ACAD just turned positive on October 15, 2026. Looking at past instances where ACAD's MACD turned positive, the stock continued to rise in 33 of 46 cases over the following month. The odds of a continued upward trend are 72%.
ACAD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 10-day moving average for ACAD crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 9 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACAD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
The Aroon Indicator for ACAD entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 28 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. ACAD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.678) is normal, around the industry mean (2.973). P/E Ratio (8.987) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (4.168) is also within normal values, averaging (438.009).
The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACAD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.
ACAD | ||
|---|---|---|
OUTLOOK RATING 1..100 | 3 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 82 Overvalued | |
PROFIT vs RISK RATING 1..100 | 87 | |
SMR RATING 1..100 | 28 | |
PRICE GROWTH RATING 1..100 | 76 | |
P/E GROWTH RATING 1..100 | 85 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| AARD | ACAD | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 67% | 1 day ago 65% |
| Stochastic ODDS (%) | 1 day ago 90% | 1 day ago 72% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 73% |
| MACD ODDS (%) | 1 day ago 82% | 1 day ago 72% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 75% |
| TrendMonth ODDS (%) | 1 day ago 86% | 1 day ago 70% |
| Advances ODDS (%) | 2 days ago 87% | 3 days ago 75% |
| Declines ODDS (%) | 4 days ago 86% | 10 days ago 68% |
| BollingerBands ODDS (%) | 1 day ago 75% | 1 day ago 68% |
| Aroon ODDS (%) | 1 day ago 78% | 1 day ago 72% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AARD’s FA Score shows that 1 FA rating(s) are green while ACAD’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AARD’s TA Score shows that 4 TA indicator(s) are bullish while ACAD’s TA Score has 5 bullish TA indicator(s).
AARD (@Biotechnology) experienced а +13.66% price change this week, while ACAD (@Biotechnology) price change was +3.04% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
AARD is expected to report earnings on Nov 12, 2026.
ACAD is expected to report earnings on Nov 04, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor tells us that AARD and PULM have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AARD and PULM's prices will move in lockstep.
| Ticker / NAME | Correlation To AARD | 1D Price Change % | ||
|---|---|---|---|---|
| AARD | 100% | -10.43% | ||
| PULM - AARD | 31% Poorly correlated | -9.55% | ||
| TWST - AARD | 30% Poorly correlated | -9.16% | ||
| ACAD - AARD | 29% Poorly correlated | +0.59% | ||
| BCYC - AARD | 28% Poorly correlated | +1.96% | ||
| TSHA - AARD | 28% Poorly correlated | -2.79% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RQI | 11.29 | 0.18 | +1.62% |
| COHEN & STEERS QUALITY Income REALTY FUND | |||
| KOLD | 29.99 | 0.47 | +1.59% |
| ProShares UltraShort Bloomberg Natural Gas (KOLD) | |||
| MMAY | 33.51 | -0.07 | -0.21% |
| Pacer Swan SOS Moderate (May) ETF (MMAY) | |||
| FEBZ | 40.82 | -0.40 | -0.97% |
| TrueShares Structured Outcome (February) ETF (FEBZ) | |||
| JPEM | 63.12 | -0.83 | -1.30% |
| JPMorgan Diversified Return Emerging Markets Equity ETF (JPEM) | |||